La galena coment que diversos estudios revelaron que la semaglutida solo bajaba la glicemia en pacientes diabticos y que el riesgo de hipoglucin (bajn de azcar) era muy mnimo en pacientes no diabticos , por tanto, se autoriz la comercializacin de otro GLP, la liraglutida ( Saxenda ) que est comercializado para perder peso y est aprobado para perder peso
Given that sensory or gastrointestinal adverse effects, such as dysgeusia and persistent nausea, can impair nutritional intake and lead to early treatment discontinuation (particularly in vulnerable populations) future research must incorporate rigorous sensory testing, larger and more diverse cohorts, and adherence-related outcomes to clarify how incretin therapies influence taste perception and long-term eating behavior (153, 157, 161)
Recovery emerges as another common theme
doi: 10.3390/metabo8040090 270 ChiabrandoDVinchiFFioritoVMercurioSTolosanoE
doi:10.1530/eje.1.02128 [5] Arduc A, Aycicek Dogan B, Bilmez S Imga Nasirouglu N, Tuna MM, Isik S, Berker D, Guler S